🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I have an abstract focused on pharmacy closures for #APPAM2024 and looking for related abstracts to put together a panel. #HealthPolicy abstracts on prescription drugs or geographic access to care could fit well. Let me know if you have a potential abstract APPAM

Great discussion with Peter Neumann at CEVR’s annual meeting, where we covered everything from value-based agreements to the exciting future of brain health. As science evolves, let's prioritize value over cost and work to break access barriers for patients and families.

Congratulations to the Tufts-CEVR team for another successful annual meeting!

The CEVR Spring newsletter is out! Featuring new research in valuing health, how payers are covering cell & gene drugs, and other issues. tinyurl.com/42f3rny9 #heor #healtheconomics

Great to be #ISPORAnnual with my CEVR colleagues!

Come find me at poster 4012 to discuss CEVR SPEC database research on commercial coverage of Accelerated Approval drugs. And grab a copy of our Annual Specialty Drug Coverage Trend Report 2024! #ISPORAnnual #heor #hta

Molly Beinfeld CEVR James Chambers Peter Neumann Thanks for the chat on this work. Great research and yes I grabbed a copy of annual rpt…reading material for plane trip home!! #ISPORAnnual #heor #hta

Friday is the deadline. Submit your 46th Annual Meeting abstract for consideration today: loom.ly/pHJW4-E

We’ve updated the CEA Registry with new search and reporting tools for sponsors. Log in to see the impact of these advances! cear.tuftsmedicalcenter.org #CEA #HEOR #healtheconomics

Tufts-CEVR is #hiring for TWO positions: 1. SPEC #ResearchAssistant II: Support our research on health plan coverage of medical tech, health economics, & cost-effectiveness analyses. Strong writing & organizational skills needed. tinyurl.com/2e6pwx3d

2. SPEC #DatabaseCoordinator: Maintain & grow the SPEC Database. Work closely with our research team to examine patient access to specialty therapies. tinyurl.com/mrrnbcvb Apply now & be part of cutting-edge healthcare research!

Are you passionate about health policy, evidence, and understanding the value of health care interventions? Apply to join CEVR as a Research Associate II today! tinyurl.com/ku9pkh6b #HEOR #Hiring

In today’s Health Affairs Forefront, CEVR’s A. Alex Levine, James Chambers, and Genentech’s Stacey Kowal argue Medicare drug price negotiations should consider non-clinical benefits to patients/families as part of unmet need. #IRA #Pharma tinyurl.com/2s4ftjkn

Does #biosimilar underutilization foretell a broken biologics market? CEVR’s LaMountain, Molly Beinfeld, James Chambers and Genentech's Wong and Kim used #SPEC data to study 4 biologics w/ biosimilars. Read in Health Affairs scholar: tinyurl.com/mryxbmcw #HAScholar

Ultra-orphan drugs bring larger health benefits than orphan/non-orphan drugs, but tend to be less cost-effective. Read new research in ISPORJournals from current/former CEVRs Clifford, A. Alex Levine, Enright, Peter Neumann, and James Chambers tinyurl.com/47t95n3k

One month from today in Boston, the special symposium on cost-effectiveness analysis. Panel 2 of 5 panels is featured below. Society for Medical Decision Making (SMDM). Join us!

Join us in Las Vegas for #AMCPNexus 2024 for 2 educational sessions by James Chambers and Molly Beinfeld's presentation of Fariel LaMountain's Platinum Ribbon-winning research on adalimumab product coverage. A full list of CEVR participation can be found here: cevr.tuftsmedicalcenter.org/news/spec-part…

Great poster at #amcpnexus 2024 from Impact Education on commercial health plan coverage of anti-VEGF therapies for retinal eye diseases. Plans included step therapy in 54% of coverage policies, most often through bevacizumab. James Chambers

Great overview of how the CEVR SPEC database can inform discussions around emerging trends in specialty drug coverage. #amcpnexus2024 James Chambers

What is the outlook for US payer coverage of specialty therapies in 2025? Expect more utilization management on pricey therapies. For more insights, register for CEVR's December 4 webinar led by James Chambers here: wellforce.zoom.us/webinar/regist…